Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Ocular Bandage Gel Awaiting Return To Clinic

By Edison Stock MarketsMar 15, 2018 08:22AM ET
www.investing.com/analysis/ocular-bandage-gel-awaiting-return-to-clinic-200298326
Ocular Bandage Gel Awaiting Return To Clinic
By Edison   |  Mar 15, 2018 08:22AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Following positive data from its first Ocular Bandage Gel (OBG) pilot study, EyeGate Pharmaceuticals Inc (NASDAQ:EYEG) has filed an amended Investigational Device Exemption (IDE) application with the FDA for a second trial. If accepted, the OBG may return to human trials in Q218. Data readouts from the trials in H218 in addition to the ongoing Phase III study for EGP-437 could prompt key value inflection drivers.

Ocular Bandage Gel supports corneal health

EyeGate’s Ocular Bandage Gel is a topical eye drop based on its proprietary crosslinked thiolated carboxymethyl-hyaluronic acid (CMHA-S), a modified form of the natural polymer, hyaluronic acid (HA). HA has hydrating and healing properties when applied to the ocular surface, but it degrades rapidly. Through crosslinking, CMHA-S may adhere longer to the ocular surface and resist degradation. In Q117, EyeGate completed a pilot trial (n=39) of patients undergoing bilateral photorefractive keratectomy (PRK) surgery and found that at day 3, 83% of those receiving OBG had complete wound closure vs 54% in the standard-of-care arm.

Amended filing could lead to OBG studies in Q218

Prior to permitting the next OBG study to proceed, the FDA requested the filing of an IDE amendment detailing processes used in OBG’s manufacturing to eliminate sources that could lead to contamination or raise microbial burden risk. EyeGate anticipates it could start its next PRK study (in upto 45 subjects) in H118 and it also plans another pilot OBG study in punctuate epitheliopathies (in upto 30 patients), a common sign of moderate dry eye. Each study could report data in H218 potentially leading to pivotal studies that could drive a 510(k) de novo regulatory filing in 2019.

To read the entire report Please click on the pdf File Below:

Ocular Bandage Gel Awaiting Return To Clinic
 

Related Articles

Ocular Bandage Gel Awaiting Return To Clinic

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email